Neuraxis (NRXS) vs ProMIS Neurosciences (PMN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Neuraxis (NRXS) has outperformed ProMIS Neurosciences (PMN) over the past year, gaining 116.3% versus a loss of 35.8%. Neuraxis is the larger company by market cap ($85.0 million vs $82.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NRXS | PMN |
|---|---|---|
| Share price | $6.77 | $9.15 |
| Market cap | $85.02M | $82.05M |
| 1-day change | -0.88% | +0.33% |
| YTD return | +49.12% | +33.97% |
| 1-year return | +116.29% | -35.79% |
| 5-year return | — | -95.93% |
| EPS (TTM) | $-0.78 | $-11.65 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.33 | $27.40 |
| 52-week low | $2.21 | $6.27 |
| Distance from 52-week high | -27.44% | -66.61% |
| Analyst consensus | none | none |
| Avg. price target upside | +62.48% | +365.68% |
| Average volume | 107.27K | 83.76K |
| Shares outstanding | 12.56M | 8.97M |
| Employees | 24 | 10 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NRXS has outperformed PMN by 152.1 percentage points over the past year.
About Neuraxis
NRXS stock →NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD) and associated FD nausea symptoms.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 24 employees
About ProMIS Neurosciences
PMN stock →ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada.
Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees
NRXS vs PMN FAQ
Which is bigger, Neuraxis or ProMIS Neurosciences?
Neuraxis (NRXS) is larger, with a market capitalization of $85.02M compared with $82.05M for ProMIS Neurosciences (PMN).
Which stock has performed better over the past year, NRXS or PMN?
NRXS returned +116.29% over the past 12 months, compared with -35.79% for PMN (price return, excluding dividends). Past performance does not predict future results.
Are Neuraxis and ProMIS Neurosciences in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Electromedical & Electrotherapeutic Apparatus for Neuraxis and Biotechnology: Pharmaceutical Preparations for ProMIS Neurosciences.